NASDAQ: RANI - Rani Therapeutics Holdings, Inc.

Rentabilidade por seis meses: -70.01%
Setor: Healthcare

Cronograma de promoção Rani Therapeutics Holdings, Inc.

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies.

Mais detalhes
Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company was incorporated in 2012 and is headquartered in San Jose, California.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

Выручка 0.000979
EBITDA -0.0261
Число акций ао 0.02551 млрд
P/S 4296.54
P/BV -43.53
EV/EBITDA -165.09
Цена ао 3.18
ISIN US7530181004
Сайт https://www.ranitherapeutics.com
Валюта usd
IPO date 2021-07-30
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Alteração de preço por dia: 0% (2.12)
Alteração de preço por semana: -9.79% (2.35)
Alteração de preço por mês: -10.55% (2.37)
Alteração de preço em 3 meses: -37.09% (3.37)
Mudança de preço em seis meses: -70.01% (7.07)
Mudança de preço por ano: +5.47% (2.01)
Mudança de preço em 3 anos: -86.82% (16.09)
Mudança de preço desde o início do ano: +5.47% (2.01)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 0 0
P/BV 3.31 5
P/E 0 0
EV/EBITDA -1.65 0
Total: 3.13

Eficiência

Nome Significado Nota
ROA, % -58.65 0
ROE, % -264.03 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.4611 10
Total: 7.8

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 175.79 10
Rentabilidade Ebitda, % 150.1 10
Rentabilidade EPS, % -6.2 0
Total: 6.6
Mais detalhes

Instituições Volume Compartilhar, %
Vanguard Group Inc 668347 2.57
Nan Fung Group Holdings Limited 493584 1.9
United Services Automobile Association 481300 1.85
Alphabet Inc. 448492 1.72
Bank of America Corporation 114259 0.44
Geode Capital Management, LLC 113629 0.44
Blackrock Inc. 63583 0.24
Lasry, Marc 62887 0.24
Alpha Square Group S, LLC 58946 0.23
King Luther Capital Management 56129 0.22

ETF Compartilhar, % Rentabilidade para o ano, % Dividendos, %
Dimensional International Core Equity 2 ETF 0.00033 17.713295799047 3.69996
Dimensional International Small Cap ETF 0.00065 18.692449355433 3.34747
Dimensional International Small Cap Value ETF 0.00059 18.789944610141 4.55441



Supervisor Cargo Pagamento Ano de nascimento
Mr. Mir A. Imran Executive Chairman 80k 1956 (68 anos)
Mr. Talat Imran CEO & Director 450k 1982 (42 ano)
Mr. Svai S. Sanford Chief Financial Officer 416k 1970 (54 ano)
Dr. Mir Hashim Chief Scientific Officer 416k 1960 (64 ano)
Mr. Eric Groen General Counsel N/A 1971 (53 ano)
Ms. Bella Vazquez Vice President of Human Resources N/A
Ms. Kate McKinley M.B.A. Chief Business Officer N/A 1977 (47 anos)
Ms. Arvinder Dhalla Vice President of Clinical Development N/A

Endereço: United States, San Jose. CA, 2051 Ringwood Avenue - abrir no Google Maps, abrir mapas Yandex
Site: https://www.ranitherapeutics.com